Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

Ozempic is an injectable anti-diabetic treatment that became wildly popular on social networks for its slimming properties.

Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe ...

Bitcoin’s strength has also fueled discussions of strategic Bitcoin reserves (SBRs) worldwide, in the US and major countries, including Germany, Russia and Brazil. More and more companies are ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks Jim Cramer recently talked about. Jim Cramer, the host of Mad Money, has been ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...

US FDA Approves Novo Nordisk's Ozempic to Cut Risk of Diabetic Kidney Disease Progression (Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

(ABC 6 News) – On Monday, Attorney General Keith Ellison announced a settlement with Novo Nordisk that let’s Minnesotans buy its insulin products for $35 per month. For the next five years ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned to the trickier task of finding a way to lose fat while retaining muscle.